Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Focus
MRNA logo

Moderna's Q3 Revenue Plunges 45% as Pipeline Advances in Oncology and Flu

MRNA10-QFiling Date: 11/7/2025
Moderna, Inc.
Description

What this story covers

Moderna's Q3 2025 revenue fell 45% to $1B amid normalizing COVID demand, with net loss at $200M. Cost cuts improved cash use, while pipeline highlights include flu vaccine Phase 3 success and oncology progress, offsetting CMV setback. Liquidity remains robust at $6.6B.

Story snapshot

CompanyModerna, Inc.
TickerMRNA
VariantStandard detailed
Duration9:42
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0001682852-25-000075

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in